US-based Boston Scientific has launched the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES), in Japan.
The next generation DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval.
The Promus Premier stent system is designed to provide physicians improved DES performance in treating patients with coronary artery disease. It features unparalleled visibility and low recoil, plus exceptional radial strength and fracture resistance.
It is reportedly the only platform to feature customised platinum chromium (PtCr) stent architecture, the market-leading everolimus drug coating and fluorinated co-polymer, and an enhanced low-profile delivery system.
Boston Scientific Japan president and representative director Yusuke Naiki said it is his great pleasure to be able to provide the Promus Premier stent system to physicians and patients in Japan.
"This innovative stent enhances our portfolio of coronary intervention products, and we believe it will strengthen our position in Japan’s DES market," Naiki added.
Boston Scientific president interventional cardiology Kevin Ballinger said the Promus Premier stent system reflects company’s commitment to DES technology and to providing interventional cardiologists with the most complete portfolio of clinical solutions.
"Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific’s overall growth strategy in the DES market," Ballinger added.
Earlier in 2013, the company obtained both CE Mark and the US Food and Drug Administration approvals for the Promus Premier stent system.